IMC Chicago’s BioMarin Pharmaceuticals BMRN Stock Holding History

IMC Chicago’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.99M	Sell	52,900 -11,100	-17%	-$647K	﹤0.01%	2223
2025 Q4	$3.8M	Buy	64,000 +34,700	+118%	+$1.89M	﹤0.01%	1939
2025 Q3	$1.59M	Buy	29,300 +10,400	+55%	+$595K	﹤0.01%	2403
2025 Q2	$1.04M	Sell	18,900 -900	-5%	-$53K	﹤0.01%	2448
2025 Q1	$1.4M	Buy	+19,800	New	+$1.33M	﹤0.01%	2040
2023 Q4	–	Sell	-11,500	Closed	-$1.02M	–	1812
2023 Q3	$1.02M	Sell	11,500 -7,300	-39%	-$650K	﹤0.01%	1219
2023 Q2	$1.63M	Sell	18,800 -9,100	-33%	-$856K	﹤0.01%	937
2023 Q1	$2.71M	Sell	27,900 -8,300	-23%	-$860K	﹤0.01%	774
2022 Q4	$3.75M	Buy	36,200 +23,700	+190%	+$2.22M	0.01%	682
2022 Q3	$1.06M	Buy	+12,500	New	+$1.11M	﹤0.01%	915
2022 Q1	–	Sell	-22,700	Closed	-$2.01M	–	1091
2021 Q4	$2.01M	Sell	22,700 -20,800	-48%	-$1.72M	﹤0.01%	817
2021 Q3	$3.36M	Sell	43,500 -15,300	-26%	-$1.21M	﹤0.01%	716
2021 Q2	$4.91M	Buy	58,800 +1,100	+2%	+$87.2K	0.01%	593
2021 Q1	$4.36M	Sell	57,700 -6,500	-10%	-$531K	0.01%	599
2020 Q4	$5.63M	Buy	64,200 +47,600	+287%	+$3.77M	0.01%	523
2020 Q3	$1.26M	Buy	+16,600	New	+$1.68M	﹤0.01%	680

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IMC Chicago's BMRN Position: Q1 2026 in Review

IMC Chicago opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 5,600 shares worth $316K. The stake represents ﹤0.01% of the portfolio and ranks #4534 among its holdings. This is a return to the name: IMC Chicago previously reported a position in BMRN as recently as Q2 2025.

IMC Chicago first reported a position in BMRN in Q4 2018 and has held it in 5 quarters since. The position peaked at $1.82M in Q1 2021. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

IMC Chicago held 5,600 shares of BioMarin Pharmaceuticals worth $316K as of Q1 2026.
BioMarin Pharmaceuticals was a new IMC Chicago position in Q1 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #4534 holding.
IMC Chicago first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 5 quarters since.
IMC Chicago's BioMarin Pharmaceuticals position peaked at $1.82M in Q1 2021.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.